Evidence map›Paper›PMID 31861195›Full record

ArticleInternational journal of molecular sciences2019

Sphingosine-1-Phosphate Enhances α

Cecília R Panta, Éva Ruisanchez, Dorottya Móré, Péter T Dancs, Andrea Balogh, Ágnes Fülöp, Margit Kerék, Richard L Proia, Stefan Offermanns, Gábor J Tigyi and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Cecília R PantaInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0003-4162-0882
Éva RuisanchezInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Dorottya MóréInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Péter T DancsInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Andrea BaloghInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Ágnes FülöpInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Margit KerékInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Richard L ProiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD 20892, USA.ORCID 0000-0003-0456-1270
Stefan OffermannsMax Planck Institute for Heart and Lung Research, 61231 Bad Nauheim, Germany.
Gábor J TigyiInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Zoltán BenyóInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0001-6015-0359
Semmelweis University · HUMax Planck Institute for Heart and Lung Research · DENational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Ligand Recognition by Phospholipid Growth Factor ReceptorsR01CA092160 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 2001 to 2022
$5.9M
Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the Molecular Biology thematic program of the Semmelweis Univers EFOP-3.6.3-VEKOP-16-2017-00009Hungarian National Research, Development and Innovation Office K-101775, K-112964, K-125174 and NVKP_16-1-2016-0042NCI NIH HHS R01 CA092160
6 · The paper itself

Abstract

Sphingosine-1-phosphate (S1P) has been implicated recently in the physiology and pathology of the cardiovascular system including regulation of vascular tone. Pilot experiments showed that the vasoconstrictor effect of S1P was enhanced markedly in the presence of phenylephrine (PE). Based on this observation, we hypothesized that S1P might modulate α

Indexed as

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAmidesAnimalsDrug SynergismLysophospholipidsMice, Inbred C57BLMice, KnockoutPhenylephrinePyridinesReceptors, Adrenergic, alpha-1rho-Associated KinasesSignal TransductionSphingosineSphingosine-1-Phosphate ReceptorsVasoconstrictionVasoconstrictor Agents1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAmidesfasudilLysophospholipidsPhenylephrinePyridinesReceptors, Adrenergic, alpha-1rho-Associated KinasesSphingosinesphingosine 1-phosphateSphingosine-1-Phosphate ReceptorsVasoconstrictor AgentsVasodilator AgentsY 27632cardiovascular diseaseG 12/13 proteinshyperreactivityRho kinaseS1P2 receptorssphingosine-1-phosphatevascular smooth muscleα1-adrenoreceptors

Identifiers

PMID31861195
PMCPMC6941080
OpenAlexW2995999705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.